With a diagnosis of mixed connective tissue disease (positive RNP antibodies, elevated creatine kinase and erythrocyte sedimentation rate, brain MRI changes), can I expect to live a normal, healthy life and retain the ability to father children?

You Can Absolutely Live a Normal, Healthy Life and Father Children with MCTD

With proper treatment and monitoring, most men with mixed connective tissue disease (MCTD) can expect to live normal, productive lives and successfully father children. The key is early diagnosis, appropriate disease control, and understanding which medications are safe for fertility and fatherhood.

Your Fertility and Ability to Father Children

The good news is that MCTD itself does not directly impair male fertility or your ability to father healthy children 1. The 2020 ACR guidelines specifically address paternal medication use in rheumatic diseases and provide clear reassurance: there are no reports of post-conception teratogenesis attributable to medications taken by men with rheumatic diseases, and post-conception exposure of the embryo or fetus through seminal fluid is minimal 1.

Medication Considerations for Fatherhood

Most medications used to treat MCTD are safe to continue when planning to father a child 1:

Strongly recommended to continue:

• Hydroxychloroquine
• Azathioprine/6-mercaptopurine
• Colchicine
• All TNF inhibitors
• NSAIDs

Conditionally recommended to continue:

• Methotrexate (despite drug label warnings, data show no evidence of mutagenesis or teratogenicity) 1
• Mycophenolate mofetil
• Leflunomide
• Sulfasalazine (may affect sperm count; get semen analysis if conception delayed) 1

Must discontinue:

• Cyclophosphamide (stop 3 months before attempting conception - can impair spermatogenesis) 1
• Thalidomide (stop 4 weeks before attempting conception) 1

Your Life Expectancy and Quality of Life

MCTD has a variable but generally manageable prognosis. Here's what the evidence shows:

The Spectrum of Outcomes

Research demonstrates three general patterns 2:

• One-third of patients: Clinical symptoms go into long-term remission, and anti-RNP antibodies may even disappear
• One-third of patients: Stable disease with manageable symptoms
• One-third of patients: Progressive disease requiring more aggressive management

What Determines Your Outcome

The most critical factor is pulmonary hypertension, which is the primary cause of premature death in MCTD 2. This involves proliferative vascular abnormalities in small pulmonary vessels rather than interstitial lung disease. Your brain MRI changes and elevated inflammatory markers (CK, ESR) indicate active disease that needs control, but these don't automatically predict a poor outcome.

Key Monitoring Points

Given your specific findings (brain MRI changes, elevated CK and ESR):

Watch for these serious complications:

• Pulmonary hypertension - the most life-threatening complication 2
• Cardiac involvement - can occur but is manageable with treatment 3
• Neurological complications - your brain MRI changes need close monitoring, though myelopathy is extremely rare 4

Regular screening should include:

• Echocardiography to monitor for pulmonary hypertension
• Pulmonary function tests
• Muscle enzyme monitoring (your elevated CK)
• Neurological assessment given your MRI findings

The Reality Check

You are not "fucked." While MCTD is a chronic condition requiring ongoing management, it is fundamentally different from diseases with uniformly poor prognoses. The evidence shows:

• Most patients achieve good disease control with appropriate treatment 2, 5
• Fertility and fatherhood are absolutely achievable with proper medication management 1
• Many patients experience long-term remission 2
• Even those with persistent disease often maintain good quality of life with manageable symptoms like arthritis and fatigue 2

Critical Caveats

Don't ignore warning signs: If you develop progressive shortness of breath on exertion, this could indicate pulmonary hypertension and requires immediate evaluation 2. This is the complication that most significantly impacts survival.

Disease evolution: Some MCTD patients (approximately 13% in one study) may evolve into other defined autoimmune diseases like SLE over 1-6 years 5. Patients with alopecia, proteinuria, thrombocytopenia, or low complement are more likely to evolve into SLE 5.

Your brain MRI findings: While neurological involvement in MCTD is rare, your brain changes warrant close monitoring. Myelopathy in MCTD, though extremely rare (only 9 cases reported globally as of 2019), has high morbidity when it occurs 4. Ensure your rheumatologist and neurologist are coordinating care.

Bottom Line

Start aggressive disease control now, maintain regular monitoring for pulmonary hypertension, and work with your rheumatologist to optimize your medication regimen for both disease control and future fatherhood. The vast majority of men with MCTD live full lives, have successful careers, father healthy children, and maintain good quality of life with appropriate treatment. Your diagnosis is serious and requires lifelong management, but it is absolutely compatible with the normal, healthy life and family you're hoping for.